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FAMILY CAREGIVING PROCESSES INDIRECTLY INFLUENCE HSCT RE-
CIPIENT QOL
Eldredge, D.H.1, Nail, L.M.1, Grant, M.2, Maziarz, R.T.1 1. Oregon
Health & Science University, Portland, OR; 2. City of Hope Medical
Center, Duarte, CA.
Background/purpose: Family caregivers (FCGs) provide much
of the outpatient care for allogeneic HSCT recipients following
stem cell transplantation. Despite the importance of family care-
giving, there is little information about how caregiving inﬂuences
the quality of life (QOL) of the HSCT recipients. The purpose of
this study is to describe the inﬂuence of family caregiving process
variables (preparedness for caregiving, predictability of caregiving,
amount of and strain from caregiving) and recipient function on
both FCG and recipient QOL.
Sample: Thirty-seven FCG-recipient dyads were recruited from
two academic medical centers on the West Coast. Both dyad
members completed questionnaires at day 45 and again at day 100
after allogeneic HSCT.
Data analysis: Descriptive statistics, correlation, and simulta-
neous regression techniques were used in this repeated measures
study. Results: QOL was measured in 4 domains: physical, psy-
chological, social, and spiritual. Recipients reported the lowest
QOL scores in social domain and the most disruption in emotional
functioning at both times. Recipients’ overall QOL scores declined
during this interval (6.2 vs 5.8; paired t  2.08; P  .04). FCGs
reported that providing emotional support was the most difﬁcult
caregiving activity and also reported the lowest quality of life in the
psychological domain. FCGs overall QOL scores remained stable
during the study interval (6.0 vs 5.7; ns). At day 45, the combina-
tion of preparedness, predictability, caregiving strain, and recipient
function accounted for 39% of the variance in FCG QOL (F,725 
3.88; P  .005); however, none of these variables were unique
predictors of FCG QOL. At day 100, this set of variables did not
explain FCG QOL. The set of caregiving process variables did not
explain recipient QOL. However, the combination of disruption in
recipient function and FCG QOL accounted for 26% of the
variance in recipient QOL at day 45; both recipient function (t 
2.06, P  .05) and FCG QOL (t  2.09; P  .04) uniquely
predicted recipient QOL. Recipient QOL at day 100 was not
explained by recipient function or FCG QOL. Conclusions: At
day 45, caregiving process variables inﬂuence FCG QOL, but do
not have direct inﬂuence on recipient QOL. FCGs need ongoing
assistance to provide emotional support to HSCT recipients. One
way to improve recipient QOL may be to address FCG concerns
about recipient functional status.
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GIANT CONDYLOMATA ACUMINATA: A RARE COMPLICATION OF AL-
LOGENEIC BONE MARROW TRANSPLANTATION
Ganguly, S.1, Waller, S.1, Skikne, B.1 University of Kansas Medical
Center, Kansas City, KS.
Introduction: Human Papilloma Virus (HPV) types 16 and 18
cause instability of P53 tumor suppressor gene and have the po-
tential to cause ano-genital carcinoma. In patients with chronic
graft-versus-host disease (GVHD), ongoing use of immunosup-
pressive agents may cause rapid replication of HPV with a subse-
quent risk of malignant transformation. We identiﬁed one case of
giant condylomata acuminata among 312 allogeneic marrow trans-
plantation recipients at University of Kansas Medical Center be-
tween 1977 and 2005. Case Report: A 38-year-old male was seen
in June 2005 at post-transplant follow-up clinic with painful anal
lesions and constipation. He had a past history of chronic myeloid
leukemia for which he underwent HLA matched sibling donor
stem cell transplantation in 2003. Since then, his course had been
complicated by GVHD involving skin, mucosa, and liver. He had
been maintained on tacrolimus, mycophenolate, mofetil, and pred-
nisone for the treatment of chronic GVHD. On examination, he
was found to have giant peri-anal condylomata acuminata occlud-
ing the anal oriﬁce. He was initially treated by surgical excision and
fulguration of condylomata. Post-procedure, he was treated with
5% imiquimod cream. He remains symptom free and without
recurrence of condylomata acuminata as of today. Biopsy of the
lesion did not show any area of malignant transformation or dys-
plasia. Immunostains were positive for HPV types 6 and 11, and
negative for types 16 and 18. Discussion: Giant condylomata
acuminata after bone marrow transplantation is rare. Due to on
going chronic GVHD in our patient, his risk of recurrence will be
high. Malignant transformation of condylomata acuminata has
been reported in solid organ transplant patients. We hope that our
patient’s risk for malignant transformation would be low due to
absence of HPV types 16 and 18. However, we plan to follow our
patient closely and any recurrence would be treated aggressively.
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FAVORABLE LATE OUTCOMES FOLLOWING UNRELATED DONOR BONE
MARROW TRANSPLANTATION WHEN ANTI-THYMOCYTE GLOBULIN IS
USED AS A PART OF CONDITIONING
Adess, M.E.1, Toor, A.A.1, Stiff, P.J.1, Rodriguez, T.E.1, Norton, J.1,
Parthasarthy, M.1, Fox-Geiman, M.1, Smith, S.E.1, Klein, J.L.1 Bone
Marrow Transplant, Dept of Medicine, Loyola University Medical Cen-
ter, Maywood, IL.
Polyclonal anti-thymocyte globulin (ATG) ameliorates the risk
for primary graft rejection as well as acute graft-versus-host disease
(GVHD) by depleting T cells in both the host and the allograft.
However, the impact of ATG on late outcomes is less clear. We
report the results of a landmark analysis of patients who survived
beyond 90 days following unrelated donor bone marrow transplan-
tation (n  35) comparing outcomes in patients conditioned with
(n  17) or without ATG (n  18). Conditioning was with either
Busulfan/Cytoxan (n  24) or BCNU/Etoposide/Ara-C/Melpha-
lan (n  11). Most of the ATG patients (12) recieved rabbit ATG,
at a median dose of 3 mg/kg (range 2.5–9 mg/kg). The others were
given equine ATG 60 mg/kg. ATG was given on day 4 and 3.
GVHD prophylaxis consisted of tacrolimus  methotrexate in
both groups. Median age was 43 years (range 18–65; 12 female).
Diseases treated were CML (8), MDS/CMPD (7), AML (7), HD
(6), MM (3), NHL (2), and CLL (2). A median of 3 prior therapies
had been given before transplant (range 1–5) and 14 patients (39%)
had failed a prior autograft. Most patients were beyond CR1 or
CP1 (n 27). With a median follow up of 22 months (range 12–49
mo), the median survival in the no ATG cohort was 12 months and
has not been reached in the ATG cohort. The 1-year and 2-year
survival in the ATG versus no ATG cohorts are 82% versus 50%
and 60% versus 50%, respectively (P  NS by Log-Rank test).
Chronic GVHD developed in 13/18 patients not receiving ATG (7
extensive) and 8/17 (3 extensive) in ATG containing regimens (P
NS). One patient in each arm of the study rejected their graft.
Relapse rate was the same in the ATG group compared to the
non-ATG group (4/17 vs 2/18; P  NS). Lymphoid recovery was
similar in the two groups as well, absolute lymphocyte counts at
day 90 and day 180 post transplant were 500 versuss 600/mL and
700 versus 950/mL in the no ATG vs ATG cohorts. Serious
infections requiring parenteral antibiotic treatment occurred in 5
patients receiving ATG, and 9 patients in the non-ATG arm. Nine
patients have died in the no ATG cohort from relapse (2), GVHD
(2), or infection (5); whereas in the ATG cohort 6 have died of
relapse (2), GVHD (3) or infection (1). In conclusion, there is a
trend towards fewer delayed transplant related complications in
patients receiving bone marrow from unrelated donors when ATG
is used as a part of conditioning.
LYMPHOMA/MULTIPLE MYELOMA
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EQUIVALENT DISEASE FREE AND OVERALL SURVIVAL IN LYMPHOMA
PATIENTS TREATED WITH EITHER MYELOABLATIVE (MA) OR NON-
MYELOABLATIVE (NMA) CONDITIONING AND ALLOGENEIC STEM CELL
TRANSPLANT (SCT)
Tomblyn, M.R.1, Brunstein, C.1, Burns, L.J.1, Miller, J.S.1, Tan, Y.1,
Weisdorf, D.1 University of Minnesota Division of Hematology, Oncol-
ogy, and Transplantation, Minneapolis, MN.
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We compared outcomes of 141 consecutive patients who re-
ceived allogeneic SCT between 1997 and 2004 with either MA
or NMA conditioning to treat non-Hodgkin (MA 62; NMA 
53) or Hodgkin (MA  3; NMA  23) lymphoma. NMA
patients were older [MA: 42 years (4–58); NMA: 48 years
(19–66)] and more recently transplanted [1997–2000: MA  31;
NMA  10; 2001–2004: MA  34; NMA  66]. Cord blood was
used more frequently in the NMA cohort [MA: 6 (9%); NMA:
33 (43%)]. NMA patients had more advanced disease with 57
(75%) in second or greater partial remission (PR) versus 37
(57%) MA patients. Those in complete remission comprised 12
(16%) patients in the NMA cohort and 17 (26%) in the MA
cohort. The remainder were in ﬁrst PR. Thirty patients (39%),
all NMA, had prior autologous transplants. Conditioning regi-
mens consisted of CyTBI, BuCy, or Fludarabine (75 mg/m2)
Cy(120 mg/kg) TBI 13.2Gy for MA and TBI 2.0Gy plus either
Fludarabine (200 mg/m2) Cy (50 mg/kg), Bu (8 mg/kg) Flu, or
Bu Cladrabine(50 mg/m2) for NMA. GVHD prophylaxis was
primarily cyclosporine (CSA)/methotrexate in the MA cohort
(n  59) and CSA/mycophenolate mofetil in the NMA cohort
(n  76). Results are shown in Table 1. In the evaluable
population, primary neutrophil engraftment at day 28 was not
different between the MA and NMA cohorts; however, time to
ANC 500 was signiﬁcantly shorter in the NMA population.
One year treatment related mortality (TRM) was signiﬁcantly
lower for patients in the NMA cohort but the risk of relapse at
1 year was higher. Acute GVHD grade II-IV and grade III-IV
did not differ nor was there a difference in the cumulative
incidence of chronic GVHD at 1 year. Overall survival (OS) at
1 year was lower in the MA cohort but similar by 3 years of
follow-up. Disease free survival (DFS) did not differ at 1 or 3
years. Year of transplant, recipient age, stem cell source, and
related donor were not predictive of OS or DFS. For the NMA
patients, there was a suggestion that those with low grade
lymphoma (n  21) were more likely to be alive and disease free
whereas patients with T cell (n  6) or Hodgkin lymphomas
were likely to relapse or die. Prior autologous transplant, stem
cell source, and disease status did not impact outcomes in the
NMA cohort. These results suggest that the greater TRM of a
MA regimen is balanced by a greater risk of relapse with a NMA
regimen in lymphoma patients. Further investigations to deter-
mine appropriate candidates for the NMA approach are ongoing
(Table 1).
Table 1. Results
Myeloablative
(n  65)
Non-
myeloablative
(n  76) P-value
Cumulative Incidence
of Neutrophil
Engraftment at
day 28 (95% CI)
95% (89–100) 95% (90–100) NS
Days to ANC >500/
L (range)
16 (11–28) 9 (0–28) <0.01
TRM at 1 year 40% (28–52) 17% (9–26) <0.01
Relapse at 1 year 14% (5–22) 37% (25–48) 0.02
Grade II–IV acute
GVHD
43% (30–56) 58% (45–71) NS
Grade III–IV acute
GVHD
14% (6–22) 25% (15–35) NS
Chronic GVHD at 1
year
32% (20–45) 46% (33–59) NS
Median follow-up of
Survivors
{months(range)}
33 (12–66) 24 (10–49) 0.04
Overall Survival
1 year 54% (42–62) 66% (55–76) 0.07
3 years 48% (35–60) 38% (21–55) NS
Disease Free Survival
1 year 46% (34–58) 46% (35–57) NS
3 years 41% (29–54) 25% (11–39) NS
MA: n  29; NMA: n  40
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AUTOLOGOUS STEM CELL TRANSPLANTATION FOR MULTIPLE MY-
ELOMA IN PATIENTS OVER 70 YEARS: A MATCHED COMPARISON WITH
PATIENTS UNDER 65 YEARS
Kumar, S.1, Lacy, M.1, Dispenzieri, A.1, Hayman, S.1, Hogan, W.1,
Poratta, L.1, Elliot, M.1, Ansell, S.1, Johnston, P.1, Micallef, I.1,
Inwards, D.1, Gastineau, D.1, Litzow, M.1, Gertz, M.1 Mayo Clinic,
Rochester, MN.
Background: Autologous stem cell transplantation (ASCT) pro-
longs survival in patients (pts) with multiple myeloma (MM) as
shown by randomized trials. However, most studies included
younger pts, usually 65 or less, and the outcome for older pts,
especially those over 70, is unclear. We retrospectively reviewed
our experience with ASCT for MM in pts over 70 years.Methods:
We identiﬁed 35 pts with MM who were 70 years at the time of
their ASCT. We matched them to 70 pts (two matches per pt),
based on status at transplant (primary refractory, plateau phase,
relapse off therapy, or relapse on therapy), Durie Salmon stage,
high or low labeling index, conventional cytogenetics (abnormal vs
normal), presence of circulating plasma cells at time of stem cell
collection, in that order of priority. Results: The median age of
the groups were 55.3 (range, 37.3–64.8) and 71.7 (70–75.8) years
at transplant. The median time to transplant from diagnosis was
similar (6.4 for the older pts compared to 6.9 mos for the other,
P NS). Ten of the 35 older pts received reduced dose melphalan
(140 mg/2) compared to 3 pts in the control group; P  .01. The
median follow up from transplant was 10.1 months for the older pts
compared to 18 months for the control group. The overall re-
sponse rate was similar (97.1% for the older pts compared to
95.5% for the control group). Eleven (31%) of the older pts and 17
(24%) of the control pts achieved a CR (P  NS). The post
transplant progression free survival estimate at 1 year post trans-
plant was 65.3% for the older pts compared to 66% for the control
group (P  .3). The 2-year estimated overall survival from trans-
plant was similar; 58% for the older pts compared to 67% for the
control group. The overall survival from diagnosis was similar for
the two groups (P  .6). The median number of days hospitalized
was 9 days for the older population compared to 5 days for the
control group (P .37). Four pts died within the ﬁrst one hundred
days, one among the older patient group. Conclusions: ASCT is
feasible in selected pts with MM over 70 years. It is likely that older
pts were selected based on their overall performance status, a factor
that is difﬁcult to analyze in this retrospective review. Nearly 70%
of the elderly pts received full dose melphalan for conditioning
(200 mg/m2). The toxicity of transplant and outcome appears to be
similar to the younger pts. Pts with MM should not be excluded
from ASCT solely on the basis of their age.
327
PRE-TRANSPLANT POSITIVE PET/GALLIUM SCANS PREDICT POOR
OUTCOME IN RELAPSED/REFRACTORY HODGKIN LYMPHOMA (HL)
Jabbour, E.1, Hosing, C.1, Pro, B.1, Khouri, I.1, Younes, A.1,
Champlin, R.1, Fayad, L.1 University of Texas/M. D. Anderson Cancer
Center, Houston, TX.
High dose chemotherapy followed by autologous stem cell trans-
plantion (SCT) has become the standard of care in patients (pts)
with relapsed or refractory HL. Chemosensitivity, assessed by
conventional tomography, has been correlated with better disease
free survival (DFS) and outcome. We assessed the value of func-
tional imaging (FI) in pts with HL referred to MDACC and
treated with high dose chemotherapy followed by SCT from De-
cember 1999 to May 2004. Twohundred ﬁfteen pts, male 60%,
median age 31 years, (range 10–76), with nodular sclerosis type
90%, were diagnosed at stages I (2%), II (43%), III (32%), and IV
(23%). Eighty-six percent of the pts were treated with ABVD-
based regimens, 45% received adjuvant radiation therapy. Thirty-
one percent of the pts were primary refractory. Most of the pts
(90%) were salvaged with ESHAP chemotherapy, and the prepar-
ative regimen was BEAM in 80%. At the time of salvage therapy,
B symptoms were present in 60% of the pts, extra-nodal disease
was documented in 24%, and relapse beyond 12 months of re-
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